PharmaCielo Ltd. PCLOF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -49.92% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -49.92% | -- | -- |
| Cost of Revenue | -- | -- | -26.36% | -- | -- |
| Gross Profit | -- | -- | -140.39% | -- | -- |
| SG&A Expenses | -- | -- | -23.05% | -- | -- |
| Depreciation & Amortization | -- | -- | -36.06% | -- | -- |
| Other Operating Expenses | -- | -- | -367.49% | -- | -- |
| Total Operating Expenses | -- | -- | -35.69% | -- | -- |
| Operating Income | -- | -- | 25.17% | -- | -- |
| Income Before Tax | -- | -- | 50.53% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 50.53% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 50.53% | -- | -- |
| EBIT | -- | -- | 25.17% | -- | -- |
| EBITDA | -- | -- | 38.25% | -- | -- |
| EPS Basic | -- | -- | 54.59% | -- | -- |
| Normalized Basic EPS | -- | -- | 19.56% | -- | -- |
| EPS Diluted | -- | -- | 54.59% | -- | -- |
| Normalized Diluted EPS | -- | -- | 19.56% | -- | -- |
| Average Basic Shares Outstanding | -- | -- | 9.40% | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | 9.40% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |